Background. Strategies to reduce the likelihood of axillary lymph node dissection (ALND) include application of Z0011 or use of neoadjuvant chemotherapy (NAC). Indications for ALND differ by treatment plan, and nodal pathologic complete response rates after NAC vary by tumor subtype. This study compared ALND rates for cT1-2N0 tumors treated with upfront surgery versus those treated with NAC. Methods. The ALND rates for cT1-2N0 breast cancer patients were compared by tumor subtype among women undergoing upfront surgery to NAC. The avoidance of surgical morbidity, particularly lymphedema, is a major goal in the management of patients with early-stage breast cancer. Axillary treatment decision making among clinically node-negative (cN0) women has become increasingly complex given the differing indications for axillary lymph node dissection (ALND) for women managed with upfront surgery versus those treated with neoadjuvant chemotherapy (NAC). Currently, the options to minimize the likelihood of an ALND among cN0 breast cancer patients include the application of American College of Surgeons Oncology Group (ACOSOG) Z0011 trial criteria 1,2 for women undergoing upfront breast-conserving surgery (BCS) and the use of NAC to downstage microscopic axillary disease.
upfront BCS remained significantly associated with higher odds of ALND in the ER/PR ? HER2 -subtype (hazard ratio [HR], 3.35; p \ 0.001), whereas NAC versus upfront mastectomy remained significantly associated with lower odds of ALND in the HER2
? and TN subtypes (HR for HER2
? , 0.19, p \ 0.001; HR for TN, 0.25, p = 0.007). Conclusion. The study showed that ALND rates differ according to surgery type and tumor subtype secondary to differing ALND indications and nodal response to NAC. These factors can be used to personalize treatment planning to minimize ALND risk for patients with early-stage breast cancer.
The avoidance of surgical morbidity, particularly lymphedema, is a major goal in the management of patients with early-stage breast cancer. Axillary treatment decision making among clinically node-negative (cN0) women has become increasingly complex given the differing indications for axillary lymph node dissection (ALND) for women managed with upfront surgery versus those treated with neoadjuvant chemotherapy (NAC). Currently, the options to minimize the likelihood of an ALND among cN0 breast cancer patients include the application of American College of Surgeons Oncology Group (ACOSOG) Z0011 trial criteria 1,2 for women undergoing upfront breast-conserving surgery (BCS) and the use of NAC to downstage microscopic axillary disease. [3] [4] [5] Among patients with cT1-2N0 breast cancer undergoing upfront BCS and planned wholebreast radiation therapy, ALND is warranted for three or more positive sentinel lymph nodes (SLNs), whereas for women undergoing upfront mastectomy, ALND remains the standard of care in the presence of any nodal metastasis. associated with the potential for axillary nodal downstaging, the rates of a nodal pathologic complete response (pCR) differ substantially by tumor subtype. [7] [8] [9] [10] Therefore, the likelihood of minimizing the extent of axillary surgery differs by tumor biology. Given these options, the optimal treatment plan to avoid ALND for early-stage breast cancer patients remains unclear.
This study compared the rates for ALND between a cohort of patients with cT1-2N0 breast cancer undergoing upfront surgery and patients treated with NAC to better elucidate optimal strategies by tumor subtype to avoid axillary surgical morbidity.
METHODS
After Memorial Sloan Kettering Cancer Center institutional review board approval, women with cT1-2N0 breast cancer detected by physical exam (i.e., no palpable adenopathy) were identified from a prospectively maintained database. Women with a cT1-2N0 tumor meeting the ACOSOG Z0011 eligibility criteria who underwent upfront BCS between August 2010 and December 2015 were identified. Women found to have a positive SLN comprised the upfront BCS cohort (Fig. 1) , and those undergoing upfront mastectomy with a cT1-2N0 tumor from January 2008 to December 2011 comprised the upfront mastectomy group, whereas those who had a cT1-2N0 tumor treated with NAC followed by surgery between August 2009 and May 2016 comprised the NAC group. Patients found to have a positive SLN were chosen for the BCS group to provide a more fair comparison with the NAC group because clinically node-negative, estrogen receptor-positive patients infrequently receive NAC.
The cohort inclusion dates differed secondary to changes in clinical practice (application of Z0011) and available clinicopathologic data. Clinical nodal status was defined by physical exam alone. However, some patients underwent axillary imaging with or without a lymph node needle biopsy before definitive treatment at the discretion of the treating physician. Patient and tumor characteristics were recorded. Estrogen receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor 2 (HER2) neu status were recorded.
For analyses, ER/PR ? , HER2 ? , and ER/PR -HER2
? groups were combined into one HER2 ? cohort secondary to small numbers. Axillary imaging and systemic therapy details were recorded for the NAC cohort. In the upfront BCS cohort, ALND was warranted for three or more positive SLNs or gross/clinically suspicious extracapsular extension per surgeon discretion. In the upfront mastectomy cohort, ALND was indicated for any nodal metastasis (micrometastasis or macrometastasis), but not for isolated tumor cells. After NAC, ALND was indicated for any nodal metastasis, including isolated tumor cells, or failure to identify three or more negative SLNs among the cohort of patients with an upfront positive axillary lymph node biopsy.
The rates of ALND were compared by subtype between the women undergoing upfront BCS or mastectomy and those receiving NAC. The patients with bilateral breast cancer were abstracted as two separate cases.
Continuous variables were summarized using median (minimum to maximum) whereas categorical variables were summarized using number and percentage. Multivariable analysis adjusted for factors determined a priori. In all analyses, we used generalized estimating equation models with exchangeable correlation structure to account for the correlation between multiple observations from a single patient. Likelihood ratio tests were used to test for interactions between treatment received and cancer subtype. A p value lower than 0.05 was considered statistically significant. All statistical analyses were conducted using R software version 3.2.5 (R Core Development Team, Vienna, Austria). cT1 clinical T1, pN0 pathologically node-negative, pN ? pathologically node-positive patients had upfront surgery (32 women with bilateral mastectomies and two women with bilateral BCS). Table 1 compares the clinicopathologic features among the three treatment groups. The women undergoing NAC were younger, more likely to have cT2 tumors, and more likely to have triple-negative or HER2
? tumors. On final pathology, those who received NAC were less likely to have lymphovascular invasion and had smaller pathologic tumors.
Among 271 cN0 women treated with NAC, 114 underwent pre-treatment axillary ultrasound and 229 had magnetic resonance imaging (MRI), with abnormal nodes identified in 74 and 90 patients, respectively. An axillary lymph node biopsy was performed for 71 NAC patients (26%), and 27 patients (10%) had biopsy-proven nodal metastasis. Most of the women treated with NAC (90%) received an anthracycline and taxane-based regimen, with 10% of the women receiving other combination chemotherapy regimens. All the women with HER2
? tumors undergoing NAC received anti-HER2 therapy. Of 271 women receiving NAC, 85 (31%) achieved a pCR in the breast, and 45 (17%) had a documented treatment effect in the axillary lymph nodes indicating that they had been initially node positive. Overall, 40 women (15%) in the NAC cohort required ALND (35 for a positive SLN and 5 for \ 3 SLNs identified), including 13 of the 27 patients with pre-treatment biopsy-proven nodal metastases ( BCS breast-conserving surgery, NAC neoadjuvant chemotherapy, cT1 clinical T1, cT2 clinical T2, ER estrogen receptor, PR progesterone receptor, HER human epidermal growth factor a Other histologies include invasive carcinoma with neuroendocrine features (n = 4) and metaplastic (n = 11), mucinous (n = 10), papillary (n = 4), and invasive tubular (n = 1) carcinomas b HER2 status and overall tumor subtype are missing for 8 women (0.8%) in the mastectomy cohort undergoing upfront mastectomy, those with HER2 ? (36.3 vs 8%; p \ 0.001) and triple-negative tumors (25.4 vs 7%; p = 0.001) were more likely to require ALND than those receiving NAC (Table 2) . A significant interaction effect was seen between tumor subtype and treatment type for both the BCS versus the NAC cohort (p = 0.003) and the mastectomy versus the NAC cohort (p = 0.006) in the multivariable analysis with respect to whether ALND was warranted. In the multivariable analysis stratified by cancer subtype and comparing upfront BCS with NAC, receipt of NAC was associated with an increase in risk of ALND among ER/PR ? HER2 -tumors (odds ratio [OR], 3.35; p \ 0.001) ( Table 3 ). Sample size was not sufficient for examination of this effect among the other subtypes.
In the multivariable analysis with stratification by subtype and comparison of upfront mastectomy with NAC, receipt of NAC was significantly associated with a reduced likelihood of ALND among patients with HER2
? (OR, 0.19; p \ 0.001) and triple-negative tumors (OR, 0.25; p = 0.007), but this effect was not statistically significant among ER/PR ? tumors (OR, 0.62; p = 0.10) ( Table 4 ). Regardless of subtype or treatment type, the patients with lymphovascular invasion also were more likely to require ALND.
DISCUSSION
Surgical morbidity after SLNB alone is substantially less than after an ALND, with significantly lower rates of lymphedema, sensory changes, wound infection, and arm dysfunction. [11] [12] [13] The optimal treatment approach to minimize the risk of ALND is related to both tumor subtype and type of surgery.
This study found that different strategies minimize ALND rates for patients with differing tumor biology. Among a population of women with cN0 ''high-risk'' early-stage breast cancer, defined as women undergoing BCS with a positive SLN or those recommended to receive NAC, the women with ER/PR ? HER2 -tumors undergoing BCS had ALND rates less than half those seen among women treated with NAC (15 vs 34%, respectively).
Conversely, compared with women undergoing upfront mastectomy, those with a triple-negative or HER2
? tumor who received NAC had substantially reduced rates of ALND.
The reasons for these findings are twofold. First, the indications for completion ALND differ between treatment groups. Among women with cT1-2N0 breast cancer undergoing upfront BCS and radiation therapy, the results of the ACOSOG Z0011 study allow the safe avoidance of ALND for patients with one or two positive SLNs.
1,2 The long-term results from this randomized controlled trial, reported with 9.25 years of follow-up evaluation, confirmed that locoregional recurrence did not differ among the patients who underwent either SLNB alone or completion ALND, with 10-year rates for regional recurrence lower than 2% in both arms of the trial. 14 Dengel et al. 15 reported that 84% of women meeting the Z0011 criteria with a positive SLN were spared ALND by application of these criteria in clinical practice. In addition to applying the Z0011 results, a second strategy to decrease the need for ALND is the use of NAC. Studies examining SLNB after NAC for patients presenting with cN0 disease report identification and false-negative rates similar to those seen in the upfront surgery setting, with persistently lower rates of nodal positivity after NAC. 5, [16] [17] [18] [19] [20] The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 4 and NSABP B-27 3 trials as well as a single-institution report by Hunt et al. 5 all reported significantly lower rates of nodal positivity among women treated with NAC than among women undergoing upfront surgery. Subsequently, the SENTInel NeoAdjuvant (SENTINA), 21 ACOSOG Z1071, 22 and the Sentinel Node Following NeoAdjuvant Chemotherapy (SN FNAC) 23 trials evaluated the identification and false-negative rates of SLNB after NAC among clinically node-positive patients and reported acceptable (\ 10%) false-negative rates with the use of the dual-tracer technique and removal of three or more SLNs. Following these publications, SLNB after NAC has been used increasingly to minimize surgical morbidity among pathologically node-negative patients. Although all the patients included in this study were cN0 by physical exam, it is likely that a subset of patients was selected for NAC secondary to abnormal axillary imaging, a positive lymph node biopsy, or both because approximately one-third of the patients in the NAC cohort had abnormal axillary lymph nodes identified on preoperative imaging. Interestingly, the use of NAC to maximize the likelihood of sparing an ALND is not a ''one-size-fits-all'' approach. Although the rates of ALND have not been shown to differ by tumor subtype among women undergoing upfront BCS and managed according to Z0011, 24 rates of nodal pCR after NAC differ substantially by subtype.
Multiple series have reported similar trends in rates of nodal pCR after NAC, with the lowest rates seen among hormone receptor-positive HER2
-tumors (0-29%), and the highest rates seen among triple-negative (47-73%) and HER2
? tumors (49-82%). [8] [9] [10] 25 Together, these data support the findings of our study. The most prevalent breast cancer subtype (ER/PR ? HER2 -) is least likely to achieve a nodal pCR after NAC and was found to have lower ALND rates after upfront BCS, whereas tumor types associated with high nodal pCR rates were more likely to require ALND in the upfront surgery setting.
Although all patients included in this study were cN0-negative by physical examination, all upfront BCS patients were SLN-positive, whereas the NAC and upfront mastectomy cohorts included both node-positive and nodenegative patients. This comparison was intentional to allow a more meaningful comparison between a higher-risk cohort of upfront surgery patients and those being selected for NAC, although in doing so, the rates of ALND in the upfront BCS group were higher than would be found for all cT1-2N0 patients. As shown in Fig. 1 , if all cN0 ER/PR ?
HER2
-patients were considered (including the majority with pathologically node-negative disease), the ALND rate after BCS would be lower than the 15% rate reported for the node-positive patients included in this study, highlighting the substantial benefit of avoiding ALND for upfront BCS in women with this tumor subtype.
We have previously reported on a cohort of more than 5000 patients with cT1-2N0 breast cancer undergoing SLNB with either BCS or mastectomy. The findings showed an overall nodal positivity rate of 25%, with only 6% having three or more positive SLNs. 26 In the current cohort of nearly 4000 BCS patients during a 5-year period, the overall rate of nodal positivity was 17%, with no more than 3% requiring ALND across all subtypes. This finding is clinically significant because many surgeons advocate for routine axillary imaging to identify nonpalpable axillary metastases in order to triage all node-positive patients to NAC. We have previously published rates of ALND among women with cN0 disease who have abnormal axillary imaging when treated according to Z0011, with findings showing that ALND was required for only 30% of those with an abnormal axillary ultrasound. 26 This contrasts with data published by Barrio et al., 28 who reported on cN0 patients with abnormal axillary imaging who underwent NAC. The findings showed that 40% of those with an upfront abnormal axillary ultrasound required ALND after NAC. In addition, 23% of the women found to be cN0 without abnormal axillary imaging before NAC were pathologically node positive after NAC. These data support our findings showing that among cN0 patients with hormone receptor-positive, HER2
-disease eligible for BCS, axillary ultrasound and triage to NAC for abnormalappearing nodes or biopsy-proven nodal metastases would be expected to increase the need for ALND given the low rates of pCR for this tumor subtype.
For triple-negative tumors, a significant reduction in ALND after NAC versus upfront mastectomy was seen, with a nonsignificant numerically lower ALND rate noted after NAC than after upfront BCS. For a patient with a triple-negative tumor, chemotherapy remains the standard of care for T1b and larger lesions, with identical regimens used regardless whether treatment is given in the neoadjuvant or the adjuvant setting. 6 Our data showing reduced ALND rates after NAC provide a strong impetus to use this treatment strategy for cN0 patients to decrease the likelihood of ALND for patients with triple-negative cancers.
Among HER2 ? patients, the appropriate treatment path remains complex. Similar to the patients with the triplenegative subtype, the patients with HER2
? tumors were found to have significantly lower ALND rates after NAC than after upfront mastectomy, with a nonsignificant reduction in ALND after NAC compared with upfront BCS. Neoadjuvant chemotherapy remains an appropriate strategy for women aiming to downsize a primary breast tumor and to minimize ALND risk. However, the caveat for HER2
? patients is that the final pathology and nodal status may have an impact on the choice of optimal chemotherapy regimen because single-agent chemotherapy with trastuzumab may be used for small (T1) nodenegative tumors. 29, 30 For the HER2 ? subtype, a multidisciplinary approach is necessary to balance the potential for overtreatment from both a surgical and a medical perspective during selection of the optimal treatment pathway. Further study is needed to assess the benefit of axillary imaging among women with HER2
? tumors to allow optimal triage to upfront surgery versus NAC.
This study was limited by its retrospective nature and the nonrandomized comparison of three different treatment cohorts with varying tumor features. In addition, the upfront mastectomy ALND rates may represent an overestimate because newer data indicate that ALND is not necessary for micrometastasis in this setting. 31, 32 Similarly, for the upfront BCS cohort, ALND was considered warranted for more than three positive SLNs as well as for gross/clinically significant extracapsular tumor extension. The ACOSOG Z0011 study did not define a volume of microscopic extracapsular extension that mandated ALND, and this often is left to surgeon judgment. One study reported that more than 2 mm of extracapsular extension was associated with a heavy nodal disease burden. 33 However, the need for ALND because of extracapsular extension remains an ongoing area of debate. Even with these limitations, we believe the findings in this study will aid in counseling patients interested in optimizing avoidance of ALND.
CONCLUSION
Use of NAC is associated with lower ALND rates for cN0 patients with triple-negative and HER2
? subtypes than treatment with initial mastectomy, whereas women with ER/PR ? HER2 -tumors have lower rates of ALND with upfront BCS than with NAC. The type of planned breast surgery and subtype can be used to personalize treatment planning to minimize ALND risk for early-stage breast cancer patients.
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